BR112021026812A2 - Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos - Google Patents
Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmosInfo
- Publication number
- BR112021026812A2 BR112021026812A2 BR112021026812A BR112021026812A BR112021026812A2 BR 112021026812 A2 BR112021026812 A2 BR 112021026812A2 BR 112021026812 A BR112021026812 A BR 112021026812A BR 112021026812 A BR112021026812 A BR 112021026812A BR 112021026812 A2 BR112021026812 A2 BR 112021026812A2
- Authority
- BR
- Brazil
- Prior art keywords
- psma
- ligands
- specific membrane
- membrane antigen
- prostate specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015 | 2019-07-02 | ||
| PCT/EP2020/068386 WO2021001360A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (psma) ligands and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026812A2 true BR112021026812A2 (pt) | 2022-02-22 |
Family
ID=67145647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026812A BR112021026812A2 (pt) | 2019-07-02 | 2020-06-30 | Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (es) |
| EP (1) | EP3993837A1 (es) |
| JP (1) | JP2022538478A (es) |
| KR (1) | KR20220044496A (es) |
| CN (1) | CN114341118A (es) |
| AR (1) | AR119331A1 (es) |
| AU (2) | AU2020299974A1 (es) |
| BR (1) | BR112021026812A2 (es) |
| CA (1) | CA3144557A1 (es) |
| CL (1) | CL2021003525A1 (es) |
| CO (1) | CO2021017708A2 (es) |
| IL (1) | IL289039A (es) |
| MX (1) | MX2022000136A (es) |
| TW (1) | TW202114742A (es) |
| WO (1) | WO2021001360A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115484991A (zh) * | 2020-04-29 | 2022-12-16 | 诺华股份有限公司 | 用于放射性标记psma结合配体的方法及其试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2415709A1 (en) | 2000-07-11 | 2003-01-10 | Bml, Inc. | Remedies for bone diseases |
| DE202014011600U1 (de) * | 2013-10-18 | 2023-05-31 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs |
| CN114716387A (zh) * | 2016-03-22 | 2022-07-08 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| IL276528B1 (en) * | 2018-02-06 | 2024-07-01 | Univ Johns Hopkins | Halogen-labeled urea-polyaminocarboxylates targeting PSMA for cancer radiotherapy |
| US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko unknown
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en active Application Filing
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-06-30 JP JP2021578240A patent/JP2022538478A/ja active Pending
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039A/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL289039A (en) | 2022-02-01 |
| EP3993837A1 (en) | 2022-05-11 |
| CO2021017708A2 (es) | 2022-05-20 |
| CN114341118A (zh) | 2022-04-12 |
| CL2021003525A1 (es) | 2022-10-21 |
| US20230226227A1 (en) | 2023-07-20 |
| WO2021001360A1 (en) | 2021-01-07 |
| KR20220044496A (ko) | 2022-04-08 |
| AR119331A1 (es) | 2021-12-09 |
| AU2024200850A1 (en) | 2024-02-29 |
| CA3144557A1 (en) | 2021-01-07 |
| MX2022000136A (es) | 2022-04-27 |
| AU2020299974A1 (en) | 2022-01-27 |
| JP2022538478A (ja) | 2022-09-02 |
| TW202114742A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110056A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
| EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| BR112018074981A2 (pt) | tratamentos de câncer | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| BR112022001520A2 (pt) | Complexo de peptídeos bicíclicos em heterotandem | |
| UY38080A (es) | FORMULACIÓN FARMACÉUTICA DE pH BAJO | |
| BR112022009938A2 (pt) | Compostos macrocíclicos substituídos e métodos de tratamento relacionados | |
| CL2009001065A1 (es) | Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros. | |
| CO2021009053A2 (es) | Inhibidores de apol1 y sus métodos de uso | |
| UY31114A1 (es) | Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos | |
| CY1107294T1 (el) | Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες | |
| AR046068A1 (es) | Anticuerpos de factor tisular y uso de los mismos | |
| CR8766A (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| MD3393478T2 (ro) | Terapie combinată | |
| EA201890282A1 (ru) | Улучшенные ингибиторы простатического специфического мембранного антигена (псма), меченные 18f, и их применение в качестве визуализирующих агентов при раке простаты | |
| BR112018075300A2 (pt) | métodos para tratamento do mal de alzheimer | |
| CL2009001215A1 (es) | Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer. | |
| CL2008000254A1 (es) | Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer. | |
| AR048534A1 (es) | Formulaciones de acetato de bazedoxifeno | |
| DOP2010000188A (es) | Una vacuna de vih que comprende una proteina y un agente estabilizador | |
| NO341574B1 (no) | Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode. | |
| CL2023000630A1 (es) | Anticuerpos anti-ceacam5 y sus conjugados y usos. | |
| BR112022005026A2 (pt) | Conjugados terapêuticos | |
| BR112021023595A2 (pt) | Formulações de agentes de imagem de psma | |
| BR112021026812A2 (pt) | Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos |